▶ THYMOSIN Α-1 · SUBTOPIC · DOSING LITERATURE

THYMOSIN α-1 Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of THYMOSIN α-1. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for THYMOSIN α-1 reports the following route(s) of administration: Subcutaneous (approved Zadaxin in non-US jurisdictions). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of THYMOSIN α-1.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for THYMOSIN α-1 of approximately ~2 hours plasma (subcutaneous). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of THYMOSIN α-1. Refer to the original publication for full protocol detail.

Goldstein AL, Hannappel E (2009) reports the THYMOSIN α-1 protocol used in From lab to bedside: emerging clinical applications of thymosin alpha 1, published in Expert Opin Biol Ther. PMID 19392576. See the source for the protocol-level dose range, frequency, and duration. link
Wu J, Zhou L, Liu J, et al. (2013) reports the THYMOSIN α-1 protocol used in The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicentre, single-blind, randomized and controlled trial, published in Crit Care. PMID 23327199. See the source for the protocol-level dose range, frequency, and duration. link
Liu Y, Pan Y, Hu Z, et al. (2020) reports the THYMOSIN α-1 protocol used in Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019, published in Clin Infect Dis. PMID 32442287. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ Approved dose?

Standard approved dosing in non-US jurisdictions is subcutaneous 1.6 mg twice weekly for 6-12 months in hepatitis B/C. This wiki does not recommend any US off-label dose.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only in the United States.

WADA · Not currently listed on the WADA Prohibited List.

◀ THYMOSIN Α-1 OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19